Click on headlines below to download research
Termination of coverage
Termination of coverage - Treatt | 08/01/2024
Edison Investment Research is terminating coverage on Kinarus Therapeutics (KNRS), Numis Corporation (NUM), EMIS Group (EMIS), Pixium Vision (PIX) and…
Return to growth in FY23
Treatt | 30/11/2023
Treatt’s FY23 results show a significantly improved y-o-y operating performance, delivering revenue and profit growth alongside record cash generation.…
FY23 profits in line despite headwinds
Treatt | 16/10/2023
Treatt’s FY23 trading update demonstrated a resilient performance despite the tougher trading environment towards the end of the year. Revenue growth…
A strong start to the year
Treatt | 10/05/2023
Treatt’s H123 results demonstrate that the business is back to greater stability and resilience. The growth was particularly impressive in Citrus,…
Strong revenue growth, profit in line
Treatt | 17/04/2023
After the usual slower start to the year, Treatt has had a strong Q2; H123 sales growth was 8.5% at constant currency. Momentum is expected to continue…
Back to steady growth
Treatt | 30/01/2023
Treatt’s AGM trading update suggests a more normal and steady pattern of trading has resumed, following the setbacks that caused the profit warning…
Rebuilding confidence
Treatt | 01/12/2022
Treatt’s FY22 results were in line with the revised guidance issued in August. Management once again explained the steps that have been taken to…
Holding steady
Treatt | 14/10/2022
Treatt’s FY22 trading update was in line with the reduced guidance issued on 15 August, ie adjusted PBT of £15–15.3m. Revenue growth of…
Rebasing expectations
Treatt | 07/09/2022
Treatt’s unexpected trading statement of 15 August reduced FY22 pre-tax profit guidance to a range of £15.0–15.3m versus our previous…